دورية أكاديمية
Biomarkers of Neurodegeneration and Alzheimer’s Disease Neuropathology in Adolescents and Young Adults with Youth-Onset Type 1 or Type 2 Diabetes: A Proof-of-Concept Study
العنوان: | Biomarkers of Neurodegeneration and Alzheimer’s Disease Neuropathology in Adolescents and Young Adults with Youth-Onset Type 1 or Type 2 Diabetes: A Proof-of-Concept Study |
---|---|
المؤلفون: | Allison L. B. Shapiro, Christina Coughlan, Brianne M. Bettcher, Meghan E. Pauley, Jeongchul Kim, Petter Bjornstad, Benjamin Rajic, Jennifer Truong, Christopher Bell, Ye Ji Choi, Keenan A. Walker, Huntington Potter, Angela D. Liese, Dana Dabelea, Christopher T. Whitlow |
المصدر: | Endocrines, Vol 5, Iss 2, Pp 197-213 (2024) |
بيانات النشر: | MDPI AG, 2024. |
سنة النشر: | 2024 |
المجموعة: | LCC:Diseases of the endocrine glands. Clinical endocrinology |
مصطلحات موضوعية: | youth-onset diabetes, Alzheimer’s disease, neurodegeneration, plasma biomarkers, amyloid, tau, Diseases of the endocrine glands. Clinical endocrinology, RC648-665 |
الوصف: | Adult-onset diabetes increases one’s risk of neurodegenerative disease including Alzheimer’s disease (AD); however, the risk associated with youth-onset diabetes (Y-DM) remains underexplored. We quantified plasma biomarkers of neurodegeneration and AD in participants with Y-DM from the SEARCH cohort at adolescence and young adulthood (Type 1, n = 25; Type 2, n = 25; 59% female; adolescence, age = 15 y/o [2.6]; adulthood, age = 27.4 y/o [2.2]), comparing them with controls (adolescence, n = 25, age = 14.8 y/o [2.7]; adulthood, n = 21, age = 24.9 y/o [2.8]). Plasma biomarkers, including glial fibrillary acidic protein (GFAP), neurofilament light chain protein (NfL), phosphorylated tau-181 (pTau181), and amyloid beta (Aβ40, Aβ42), were measured via Simoa. A subset of participants (n = 7; age = 27.5 y/o [5.7]) and six controls (age = 25.1 y/o [4.5]) underwent PET scans to quantify brain amyloid and tau densities in AD sensitive brain regions. Y-DM adolescents exhibited lower plasma levels of Aβ40, Aβ42, and GFAP, and higher pTau181 compared to controls (p < 0.05), a pattern persisting into adulthood (p < 0.001). All biomarkers showed significant increases from adolescence to adulthood in Y-DM (p < 0.01), though no significant differences in brain amyloid or tau were noted between Y-DM and controls in adulthood. Preliminary evidence suggests that preclinical AD neuropathology is present in young people with Y-DM, indicating a potential increased risk of neurodegenerative diseases. |
نوع الوثيقة: | article |
وصف الملف: | electronic resource |
اللغة: | English |
تدمد: | 2673-396X |
العلاقة: | https://www.mdpi.com/2673-396X/5/2/14Test; https://doaj.org/toc/2673-396XTest |
DOI: | 10.3390/endocrines5020014 |
الوصول الحر: | https://doaj.org/article/1b500686e7d74e3cb3f6f79643b1424aTest |
رقم الانضمام: | edsdoj.1b500686e7d74e3cb3f6f79643b1424a |
قاعدة البيانات: | Directory of Open Access Journals |
كن أول من يترك تعليقا!